When a $273 stock trades at roughly eight times next year’s earnings while the analysts who cover it carry an average price target above $340, one of two things is usually true: either the market sees a structural break in the business that the sell-side has not yet modeled, or fear about the entire sector has painted a well-positioned company with the same brush as its troubled peers. The Cigna Group (CI) is the second kind of situation. Over the past two years, the managed-care sector has been one of the worst places to put capital in U.S. large-cap healthcare, as a Medicare Advantage cost crisis, rising medical loss ratios, and a wave of political scrutiny aimed at pharmacy benefit managers (PBMs) crushed sentiment. Yet Cigna deliberately walked away from the epicenter of that storm — it sold its entire Medicare Advantage, Medicare Part D, Supplemental Benefits, and CareAllies businesses to Health Care Service Corporation (HCSC) for approximately $3.7 billion, a deal that closed in March 2025 ([Healthcare Dive](https://www.healthcaredive.com/news/cigna-hcsc-close-medicare-sale/743040/)). That single decision reshaped the risk profile of the company, and the market has not fully repriced it.
This is why Cigna is worth a fresh, detailed look right now. The company just raised its full-year 2026 adjusted EPS guidance to at least $30.45 after a second quarter in which revenue reached $71.7 billion and adjusted EPS came in at $7.78, with both operating segments beating expectations ([Simply Wall St](https://simplywall.st/stocks/us/healthcare/nyse-ci/cigna-group/news/cigna-ci-stock-stalls-as-evernorth-carries-growth-and-pbm-pr)). Consensus across roughly two dozen analysts sits near a $341 price target with a Moderate Buy rating, no Sell ratings, and a range that runs from $290 on the low end to $400 on the high end.
Three investment points frame this analysis. First, Cigna is not a health-insurance company that happens to own a PBM; it is a health-services company (Evernorth) that happens to own a focused commercial-insurance business (Cigna Healthcare). Evernorth generated $232.1 billion of external revenue in 2025 and is the profit and growth engine. Second, the Medicare Advantage exit removed Cigna’s exposure to the single most damaging cost dynamic in the industry over 2024–2026, structurally lowering earnings volatility even as competitors continue to absorb losses. Third, the valuation gap is extreme: a business compounding adjusted earnings at a high-single to low-double-digit rate, buying back enormous quantities of stock, and paying a growing dividend should not trade at eight times forward earnings unless the PBM reform narrative permanently impairs its economics — a case this article will examine directly rather than dismiss.
What follows is a full breakdown: how Cigna actually makes money, the structure and growth trajectory of the health-services and managed-care industries, the durability of Cigna’s competitive moat, a five-year financial reconstruction, a step-by-step valuation with bull/base/bear scenarios, an honest accounting of the risks (including the real PBM headwind that has caused some analysts to trim targets), and a concrete exit plan.
—
1. Company Overview
The Cigna Group is one of the largest healthcare enterprises in the United States, but its revenue mix looks very different from the “health insurer” label most investors attach to it. In 2025, the company reported total revenues of $274.9 billion, up roughly 11% year over year ([Insurance Business](https://www.insurancebusinessmag.com/us/news/life-insurance/cigna-posts-us6-billion-profit-on-doubledigit-2025-revenue-growth-564455.aspx)). The vast majority of that flows through Evernorth, not through insurance premiums. Understanding the two-segment structure is essential to understanding the thesis.
Evernorth Health Services is the health-services arm. It houses Express Scripts (one of the three PBMs that together administer the overwhelming majority of U.S. prescription drug claims), Accredo (specialty pharmacy, which dispenses high-cost drugs for complex conditions such as oncology, immunology, and rare diseases), and a growing set of care-services businesses including behavioral health, home delivery pharmacy, and benefits management. Evernorth generated external-customer revenue of $232.1 billion in 2025 (adjusted revenue of roughly $235.0 billion), making it the dominant contributor to the top line. Crucially, Evernorth serves clients well beyond Cigna’s own insurance members — it is a business-to-business services engine that sells to health plans, employers, and government programs, including a four-year agreement to keep providing pharmacy benefits to the Medicare members that moved to HCSC.
Cigna Healthcare is the benefits (insurance) segment, focused on U.S. commercial employer coverage, stop-loss insurance for self-funded employers, and international health. It generated external-customer revenue of $41.4 billion in 2025 (adjusted revenue of about $47.2 billion). This is a deliberately narrower book than peers: after the HCSC divestiture, Cigna is concentrated in the commercial/employer market — historically the most stable and profitable slice of health insurance — rather than the government-sponsored Medicare Advantage market that has driven peer earnings volatility.
The customer footprint underscores the model. In 2025, total pharmacy customers grew to 122.5 million (up about 4%), while total medical customers declined to 18.1 million (down roughly 6%) — and that medical-customer decline was overwhelmingly a function of the HCSC transaction, not organic churn ([Healthcare Finance News](https://www.healthcarefinancenews.com/news/cigna-earnings-revenues-exceed-expectations-driven-evernorth-and-healthcare-divisions)). In other words, the “shrinking” insurance membership is a feature of the strategy, not a warning sign: Cigna traded away volatile Medicare lives while its far larger pharmacy-services franchise kept growing.
On market position, Express Scripts is one of the “big three” PBMs alongside CVS Health’s Caremark and UnitedHealth’s OptumRx; those three collectively administer the large majority of U.S. prescription volume. Accredo is one of the two largest specialty pharmacies in the country. In commercial health insurance, Cigna Healthcare is a top-tier national player in the employer/self-funded market, competing with UnitedHealthcare, Aetna (CVS), and Elevance. On governance, Cigna is a widely held S&P 500 constituent with predominantly institutional ownership and modest insider holdings, run by a management team that has, over the last several years, demonstrated a clear willingness to reshape the portfolio (the VillageMD exit, the Medicare divestiture) and return capital aggressively. For 2026, management guided Evernorth to at least $6.9 billion of pre-tax adjusted income and Cigna Healthcare to at least $4.5 billion — a mix that confirms health services, not insurance underwriting, is the primary earnings driver.
—
2. Industry Analysis
2-1. Market Size and Growth Trajectory
Cigna sits at the intersection of two enormous end markets: U.S. healthcare spending broadly, and the pharmacy/health-services value chain specifically. U.S. national health expenditure runs in the multi-trillion-dollar range and has grown at a mid-single-digit compound annual rate for decades, structurally outpacing nominal GDP because of aging demographics, chronic-disease prevalence, and relentless medical-cost inflation. Within that, the prescription drug channel — where Evernorth operates — is one of the fastest-growing subsegments, driven by a wave of high-cost specialty and biologic therapies.
The pharmacy-services and PBM market is the specific arena that matters most for Cigna. PBMs sit between drug manufacturers, pharmacies, and payers, negotiating prices and rebates, managing formularies, and processing claims at massive scale. The economics are volume-driven: a PBM earns on the spread and on service fees across billions of prescriptions, so scale is destiny. The specialty pharmacy market — dispensing drugs that can cost tens of thousands to hundreds of thousands of dollars per patient per year — is growing considerably faster than traditional retail pharmacy, because the drug-development pipeline is increasingly weighted toward oncology, immunology, and rare-disease biologics. This matters enormously: specialty is where the dollars and the margins are migrating, and Accredo is one of the two largest specialty pharmacies in the U.S. Management explicitly credited “strong specialty growth” and biosimilar adoption as drivers of the raised 2026 guidance.
In terms of industry cycle position, the PBM/health-services market is in a maturation-with-mix-shift phase rather than a decline. Aggregate prescription volume grows at a low-single-digit rate, but the value mix is shifting rapidly toward specialty, which grows at a high-single to double-digit rate. The commercial health-insurance market that Cigna Healthcare serves is more mature — a low-growth, share-driven market — but it is far more profitable and stable than the government programs, which are in a painful part of their own cycle (more on that below).
2-2. Structural Growth Drivers
Driver 1 — The specialty and biosimilar wave. The single most important secular tailwind for Evernorth is the migration of drug spend toward specialty medications. As biologics come off patent, biosimilars create a new profit pool for the players who can drive adoption, manage formularies, and dispense complex therapies. Cigna has been unusually aggressive here, including launching lower-cost private-label and biosimilar products through its Quallent and related initiatives to capture the value that used to accrue almost entirely to branded manufacturers. Accredo’s scale in specialty dispensing means Cigna participates in the fastest-growing dollars in the entire drug channel. Over a five-to-ten-year horizon, the specialty share of drug spend is expected to keep climbing, and each incremental specialty script carries far more revenue and gross profit than a traditional generic fill. This is a multi-year, structurally advantaged growth engine, and it is why Evernorth revenue keeps compounding even as unit volume growth in retail pharmacy stays low.
Driver 2 — Care-services expansion and vertical integration. Beyond the traditional PBM, Evernorth has been building out adjacent care-services businesses: behavioral health, home-based and virtual care, benefits management, and integrated clinical programs. The strategic logic is to move up the value chain from processing claims to managing total cost of care, which deepens client relationships and diversifies revenue away from the commoditizing parts of the PBM. Management has repeatedly highlighted the Specialty & Care Services sub-segment as a rising share of Evernorth’s pre-tax earnings — in the second quarter of 2026 it contributed roughly $1.1 billion of pre-tax adjusted earnings. As employers and health plans increasingly want a single partner to manage pharmacy, behavioral, and clinical spend in an integrated way, Evernorth’s breadth becomes a growth driver rather than just a cost center. This is a longer-duration dynamic that should support high-single-digit earnings growth through the rest of the decade.
Driver 3 — Capital return as a per-share growth engine. Not every growth driver is organic. Cigna generates enormous operating cash flow and has committed the majority of the HCSC divestiture proceeds to share repurchases. In 2025 the company repurchased roughly 11.9 million shares for about $3.6 billion, with more buybacks embedded in the 2026 outlook, and it raised the quarterly dividend to $1.56 per share ([Simply Wall St](https://simplywall.st/stocks/us/healthcare/nyse-ci/cigna-group/news/cigna-ci-stock-stalls-as-evernorth-carries-growth-and-pbm-pr)). At eight times forward earnings, every dollar spent on buybacks retires earnings at a very high yield, mechanically accelerating EPS growth above the rate of underlying profit growth. With a share count in the mid-260-million range and billions of dollars of annual repurchase capacity, buybacks alone can add several percentage points to annual EPS growth. This is short-term-visible (the 2026 guidance already reflects it) and long-term-durable (the free cash flow that funds it is recurring).
2-3. Competitive Landscape
The health-services and managed-care industry is an oligopoly at the top, with a handful of vertically integrated giants. The comparison below frames Cigna against its most direct peers on the metrics that matter for this thesis. Figures are approximate and drawn from the most recent public data; they are meant to illustrate relative positioning, not to serve as precise point estimates.
Company Model emphasis Approx. TTM revenue Forward P/E (approx.) Key structural feature The Cigna Group (CI) PBM/specialty (Evernorth) + commercial insurance ~$282B ~8x Exited Medicare Advantage; commercial + services focus UnitedHealth Group (UNH) Integrated insurer + OptumRx/Optum Larger Higher Largest MA insurer; heavy government exposure CVS Health (CVS) Caremark PBM + Aetna insurance + retail Comparable scale Similar/lower Retail drag; large MA book Humana (HUM) Predominantly Medicare Advantage Smaller Varies Pure-play MA; most exposed to MA cost crisis Elevance Health (ELV) Blue-branded insurer + Carelon services Large Low-double-digit Blues franchise; growing services arm
Cigna’s differentiation is clearest against Humana and, to a lesser degree, UnitedHealth: those companies carry heavy Medicare Advantage exposure, which is precisely the book of business that has been hemorrhaging margin as medical costs among seniors ran far ahead of the government’s reimbursement updates. Cigna, having sold that book to HCSC, is now a commercial-and-services company. Against CVS, Cigna’s advantage is focus: it does not carry a struggling retail-pharmacy footprint. The core competitive reality is that scale in the PBM/specialty channel is the moat, and Cigna is one of only three players with the volume to compete at the top — which is exactly why the PBM-reform debate, while a genuine risk, is also a testament to how entrenched and profitable these franchises are.
—
3. Economic Moat Analysis
Moat Type 1: Efficient Scale and Cost Advantage in Pharmacy Services
The PBM/specialty-pharmacy business is a textbook efficient-scale moat. Negotiating leverage with drug manufacturers, the fixed-cost leverage of claims-processing infrastructure, and the ability to spread investment in clinical programs across a massive book all improve with volume. Express Scripts processes prescriptions for a large share of the U.S. market; that scale lets it extract better net pricing and rebates than a subscale competitor could, and it makes Evernorth the low-cost operator in the channel. The concrete evidence sits in the customer numbers: 122.5 million pharmacy customers and a book that keeps growing even as the industry consolidates. New entrants — including well-capitalized disruptors — have repeatedly discovered that without scale, they cannot match incumbent net pricing, because the rebate and negotiating economics are fundamentally volume-based. This is why the “big three” structure has proven so durable: it is not an accident of regulation but a consequence of the underlying cost curve.
Moat Type 2: Switching Costs and Integration in Specialty and Employer Benefits
The second moat is switching costs, and it is strongest in specialty pharmacy and the employer channel. Specialty drugs require complex clinical management — patient onboarding, adherence programs, prior authorization, cold-chain logistics, and coordination with prescribing physicians. Once a health plan or employer routes its specialty patients through Accredo, the operational and clinical entanglement makes switching disruptive and risky for patient outcomes. On the employer side, Cigna Healthcare’s stop-loss and self-funded relationships are sticky multi-year arrangements deeply embedded in an employer’s benefits administration. When pharmacy, behavioral, and medical benefits are integrated under one partner, the cost and risk of unwinding that integration rises sharply. The evidence of pricing power is visible in Evernorth’s ability to keep growing pre-tax adjusted income (guided to at least $6.9 billion in 2026) even amid pricing concessions on large renewals — a subscale competitor forced into the same concessions would see profits collapse, whereas Cigna’s scale and stickiness let it absorb them and still grow.
Moat Durability Assessment
Will these moats hold for five to ten years? The efficient-scale moat is highly durable — the volume-based economics of the PBM channel are structural, and the “big three” have if anything consolidated their position. The switching-cost moat in specialty is also durable, because clinical complexity keeps rising as the drug pipeline shifts toward biologics. The genuine threat to moat durability is regulatory, not competitive: the PBM model has drawn intense political scrutiny over the opacity of rebate economics, and legislation or FTC action mandating rebate pass-through, delinking compensation from list price, or forcing transparency could compress the legacy spread-based profit pool. Cigna is preemptively responding by shifting toward rebate-free and fee-based models (its own guidance reflects pricing concessions and investment in a rebate-free PBM), which is a margin headwind in the near term but a moat-preservation move in the long term. The counterargument to the regulatory bear case is that even in a fully transparent, fee-for-service PBM world, scale still wins — someone has to process billions of claims and manage specialty logistics, and the three incumbents are the only ones who can do it at cost. The moat likely survives; the shape of its profit pool is what’s genuinely in flux.
—
4. Financial Analysis
Cigna’s reported (GAAP) results are noisy because of large one-time items, so the trend must be read alongside the adjusted numbers management uses. The table below reconstructs the last four fiscal years plus the trailing twelve months, using GAAP figures for revenue, operating income, and net income.
Fiscal year Total revenue Operating income Net income (GAAP) Note 2022 $180.5B $8.45B $6.70B — 2023 $195.3B $8.54B $5.16B — 2024 $247.1B $9.42B $3.43B VillageMD impairment (~$2.7B after-tax) depressed net income 2025 $274.9B $8.15B $5.96B Revenue +11% YoY; net income recovered TTM ~$282.5B — ~$6.42B EPS (ttm) $24.18
Revenue, operating income, and net income for 2022–2025 sourced from company filings and results releases ([Insurance Business](https://www.insurancebusinessmag.com/us/news/life-insurance/cigna-posts-us6-billion-profit-on-doubledigit-2025-revenue-growth-564455.aspx)); TTM figures from Finviz.
The story behind each year matters. Revenue has compounded from $180.5 billion in 2022 to roughly $282.5 billion on a trailing basis — a striking pace for a company this size, driven almost entirely by Evernorth’s specialty and services growth. The 2024 net-income trough of $3.43 billion was not an operating collapse; it was overwhelmingly the result of a non-cash, after-tax investment loss of approximately $2.7 billion tied to the impairment of the company’s VillageMD equity stake. Strip that out and the underlying earnings power was far more stable — adjusted income from operations was roughly $7.7 billion in 2024 versus $7.4 billion in 2023. In 2025, GAAP net income recovered to $5.96 billion, and the trailing figure now sits near $6.42 billion, translating to trailing EPS of $24.18.
On a per-share basis the math is internally consistent and worth verifying: with roughly 263.7 million shares outstanding and a $273.84 share price, the market capitalization is about $72.4 billion; trailing EPS of $24.18 across 263.7 million shares reconciles to roughly $6.4 billion of net income; and the trailing P/E of 11.3 equals price divided by that EPS. The forward multiple is where the value case sharpens: management’s 2026 adjusted EPS guidance of at least $30.45, and the consensus forward adjusted EPS of roughly $33.45 for the following year, put the stock at about 8.2 times forward earnings ($273.84 ÷ $33.45).
Key operating metrics reinforce the quality of the franchise. Return on equity runs near 15.5% and return on assets near 4.3% — healthy for a capital-light services-heavy model — while the debt-to-equity ratio of about 0.75 is manageable for a company generating multiple billions of dollars in annual operating cash flow. The balance sheet supports both the dividend (recently raised to $1.56 per quarter) and the multi-billion-dollar buyback program without stress. The margin profile is thin at the consolidated level (net margin around 2%), but that is inherent to a business where most of the $282 billion of revenue is pass-through pharmacy spend; the more meaningful measure is the segment pre-tax adjusted income, guided to $6.9 billion (Evernorth) plus $4.5 billion (Cigna Healthcare) for 2026 — over $11 billion of combined segment earnings power against a $72 billion market cap. For a company that is already solidly profitable and cash-generative, the path from here is margin-mix improvement (specialty and care services carrying higher margins) plus aggressive per-share compounding through buybacks, not a speculative “path to profitability.”
—
5. Valuation
Because Cigna is durably profitable, a P/E-based approach anchored on forward adjusted earnings is the most appropriate primary method, cross-checked against the company’s own history and the peer group.
Step 1 — Establish the earnings base. Management guides 2026 adjusted EPS to at least $30.45. Consensus forward adjusted EPS for the next twelve-to-eighteen months is approximately $33.45, which is the figure implied by the reported forward P/E of 8.19 at a $273.84 price. I will value on the consensus forward figure of $33.45, treating the $30.45 guidance floor as a downside anchor.
Step 2 — Select the multiple. Managed-care and health-services peers have historically traded in a range of roughly 10x to 15x forward earnings in normal environments; Cigna itself traded around 11–13x in more stable periods. The current 8.2x reflects sector-wide fear (MA cost crisis) and PBM-reform overhang — but Cigna has largely exited the MA book that is the primary source of that fear. A conservative re-rating to 10x forward is therefore reasonable and still below the historical average.
Step 3 — Derive the base-case target. 10x × $33.45 forward adjusted EPS = approximately $335 per share, or about +22% upside from $273.84. This aligns closely with the analyst consensus target of roughly $341 (range $290–$400) ([Investing.com consensus](https://www.investing.com/equities/cigna-corp-consensus-estimates)). I agree with the consensus direction here — the base case is not a heroic assumption; it simply requires the market to stop pricing Cigna as if it still carried Humana-like Medicare Advantage risk.
Step 4 — Scenario analysis.
– Bull case (~$400, +46%): If the PBM-reform overhang clears without material profit-pool damage, Evernorth specialty growth accelerates, and buybacks shrink the share count faster than expected, the market could re-rate Cigna to ~11.5x on ~$35 of forward EPS. This maps to the top of the analyst range ($400).
– Base case (~$335, +22%): 10x on $33.45 forward adjusted EPS. Modest multiple re-rating plus mid-single-digit earnings growth plus buyback accretion.
– Bear case (~$224, −18%): If PBM legislation compresses the legacy rebate profit pool faster than the shift to fee-based models can offset, and employer/GLP-1 volume headwinds persist, forward EPS could stall near $28 and the multiple could stay depressed at 8x, implying roughly $224 — below both the current price and the 52-week low of $239.51. The downside is real, but it is cushioned by the low starting multiple and ongoing buyback support, and it requires the reform bear case to actually play out rather than merely to be feared.
The asymmetry is the point: the base case offers roughly +22%, the bull case roughly +46%, and even the bear case represents a smaller percentage loss than the base-case gain, because you are starting from eight times earnings rather than a stretched multiple. That is the classic profile of a value re-rating candidate rather than a momentum stock.
—
6. Risk Factors
Risk 1 — PBM regulatory reform and rebate-model compression. This is the most important risk and the primary reason the stock is cheap. The pharmacy-benefit-manager model has drawn sustained bipartisan political scrutiny over the opacity of rebate economics and the alignment of PBM incentives with drug list prices. Legislation or regulatory action mandating rebate pass-through, delinking PBM compensation from list prices, or forcing granular transparency could compress the legacy spread-based profit pool that has historically been a meaningful earnings contributor. This is not merely theoretical: Cigna’s own guidance already reflects pricing concessions on large renewals and investment in a rebate-free PBM model, and that dynamic has led some analysts to trim their targets on the PBM segment’s forward outlook ([Simply Wall St](https://simplywall.st/stocks/us/healthcare/nyse-ci/cigna-group/news/cigna-ci-stock-stalls-as-evernorth-carries-growth-and-pbm-pr)). The mitigant is that scale still wins in any PBM structure and Cigna is proactively migrating its model, but the transition is a genuine multi-year margin headwind and the single biggest swing factor for the bear case.
Risk 2 — GLP-1 and employer-coverage volume headwinds. The rapid rise of GLP-1 therapies (for diabetes and weight loss) is a double-edged sword. On one hand it drives specialty and pharmacy revenue; on the other, coverage decisions, high costs, and shifting employer willingness to cover these drugs create uncertainty for pharmacy volumes and PBM profitability. Cigna has flagged that reduced employer coverage and uneven uptake of GLP-1 therapies are a meaningful headwind to pharmacy volumes. Because Evernorth’s economics are volume-sensitive, swings in employer coverage decisions and drug-mix shifts can move segment profits in ways that are hard to forecast quarter to quarter, and a broad pullback in employer-sponsored coverage during an economic slowdown would pressure both segments simultaneously.
Risk 3 — Concentration and execution in a low-margin, high-revenue model. Cigna runs on razor-thin consolidated margins (net margin around 2%), which means small changes in medical cost trend, drug pricing, or rebate capture translate into large percentage swings in profit. The company is also concentrated in the commercial/employer market after the MA exit, so it is more exposed to the employment cycle: a recession that raises unemployment directly shrinks the commercial insured base and the associated pharmacy volume. Add integration and reinvestment execution risk (the rebate-free transition, care-services build-out, biosimilar launches), and the model requires consistent operational discipline. History shows this can go wrong — the $2.7 billion VillageMD impairment in 2024 is a reminder that capital-allocation missteps into care-delivery assets can destroy value even when the core business performs. Investors are underwriting management’s ability to execute a complex model at scale, and the low margin leaves little room for error.
—
7. Conclusion and Exit Plan
Investment rating: Buy. Cigna offers a rare combination in large-cap healthcare: a genuinely wide-moat, cash-generative franchise (Evernorth’s scale in PBM and specialty pharmacy), a deliberately de-risked insurance book after the Medicare Advantage exit, aggressive per-share compounding through buybacks, and a valuation — roughly eight times forward earnings — that prices in a permanent impairment of the PBM profit pool that is far from certain. The base case points to approximately $335 (+22%), the bull case to roughly $400 (+46%), and even the bear case losses are cushioned by the low starting multiple. The primary risk (PBM reform) is real and worth respecting, but it is also the source of the opportunity: the market has extrapolated the worst of the sector’s troubles onto a company that has structurally reduced its exposure to them.
Entry price range. The current $273.84 level, near the middle of the 52-week range ($239.51–$315.47), is a reasonable entry for a starter position. Investors seeking a margin of safety could scale in more aggressively toward the low $260s / upper $250s, which would push the forward multiple below 8x and widen the risk/reward further.
Exit conditions:
– Target achieved: Trim into strength as the stock approaches the base-case target of ~$335; take additional profits toward the bull-case ~$400 if the PBM-reform overhang clears and specialty growth accelerates.
– Fundamental break: Reduce or exit if PBM legislation is enacted in a form that structurally compresses Evernorth’s segment margins, if the 2026 adjusted EPS guidance floor of ~$30.45 is cut materially in a subsequent update, or if the commercial medical-cost trend deteriorates sharply.
– Time-based: Reassess after two to three quarters of results (roughly six to nine months) to confirm the buyback pace, Evernorth pre-tax income trajectory toward the ~$6.9 billion guide, and any legislative developments.
Item Detail Company The Cigna Group (CI) Current Price $273.84 Target Price $335 (base case) Upside ~+22% (to base); consensus ~$341 (~+24%) Rating Buy Key Thesis Wide-moat Evernorth engine + Medicare Advantage exit + 8x forward earnings = mispriced value Main Risk PBM regulatory reform compressing the rebate profit pool
—
This article is for informational purposes only and does not constitute investment advice. All data sourced from public filings, analyst reports, and news as of the publication date. Invest at your own discretion.
This content is general investment information provided to an indefinite/unspecified audience by a quasi-investment advisory business registered under Korea’s Financial Investment Services and Capital Markets Act, and is not personalized 1:1 investment advice tailored to any individual investor. This analysis is for informational purposes only and is not a solicitation to invest. All investment decisions and their consequences rest solely with the investor. The estimates and assumptions in this report are as of the writing date (2026-09-23) and may not materialize depending on market conditions and geopolitical variables. Financial data used reflects sources such as company filings and analyst consensus, and the scenarios and price targets represent the author’s conservative assessment. All investments carry the risk of principal loss, and past performance or analytical track record does not guarantee future results. As of the writing date, the author does not hold a position in this stock. The author’s holdings and positions may change without prior notice depending on market conditions.
함께 읽으면 좋은 글
- AMD $1 Trillion Milestone Reanalysis: After the OpenAI 6-Gigawatt Deal and a 31% Run to $613, Is There Still Upside?
- AMETEK Record $4.11B Backlog and the Acquisition Engine: Why Analysts Keep Raising Targets Toward $282 (2026 Analysis)
- Target Turnaround Analysis 2026: Why 3.8% Comps and the $2B Fiddelke Reset Point to Margin Inflection Beyond the Tariff Refund
- Circle Internet (CRCL) Stock Analysis: The Arc Launch, $73B in USDC, and Why Rate Cuts Cap the Near-Term Upside at ~$100
- Sea Limited Three-Engine Flywheel: Why Monee’s 62% Loan Growth and Shopee’s $1B EBITDA Target Point to 56% Upside in 2026